Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05082350
Other study ID # CFE/IF/28-20
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 1, 2020
Est. completion date November 30, 2021

Study information

Verified date October 2021
Source Catholic University of Murcia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease. Black garlic is the result of a fermentation process of common white garlic in which the temperature and humidity are kept constant over a long period of time. Black garlic is particularly rich in phenolic compounds such as S-allylcysteine or S-allyl-mercaptocysteine, with antioxidant action. It also provides vitamin C and other valuable antioxidant substances such as flavonoids.


Description:

A parallel, controlled clinical trial will be performed to assess the effect of garlic on mild hypercholesterolemia. The study will conducted in two groups of volunteer: healthy and at cardiovascular risk (hypercholesterolemic subjects), consuming black garlic, with each individual acting as its own control. The study will have a total duration of 18 weeks, divided in two stages: - Stage 1: basal or washout stage of 2 weeks, in which volunteer follow their usual diet with restrictions - Stage 2: intervention stage of 16 weeks, in which volunteer consume black garlic Sixty healthy volunteers (men and women) between 40-65 years old and BMI between 24.9-29.9 kg/m2 will be recruited. From the total of volunteer, 30 will correspond to the Healthy Group, which should have total blood cholesterol levels less than 200 mg/dL and LDL-cholesterol less than 135 mg/dL. The other 30 volunteers correspond to the Cardiovascular Risk Group, which should have total cholesterol levels between 200-300 mg/dL and LDL-cholesterol levels between 135-175 mg/dL. Other inclusion criteria established for all volunteers are: no acute or chronic pathology, (except hypercholesterolemia for the risk group), no taking drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism. The study has been approved by the Ethical Committee of Catholic University of Murcia (UCAM) and will be carried out in accordance with the Helsinki Declaration of Human Studies. Recruitment will take place at various Health Centers and at UCAM. All participants will be informed on the characteristics of the study and, after signing the informed consent, a routine analysis will be requested to classify the volunteer in the healthy or cardiovascular risk group. To avoid bias due to gender, the number of women and men recruited in both groups will be balanced. The size of the study population has been estimated taking total blood cholesterol level as the main variable and taking into account that the study design is randomized and parallel. Considering a statistical power of 80%, a statistical significance level of 5% (one tail), a standard deviation of 6.5, aiming to estimate a difference of 2.5, the number of volunteers required is 25 for each group, rising to 30 in anticipation of dropouts. This number, being two study groups, will allow obtaining results with statistical significance in other biochemical parameters that would be determined as secondary variables of the study and that would inform on the effect of black garlic consumption on cardiovascular function and associated dysfunctions (inflammation, hypertension, endothelial function, diabetes, etc.). After an initial washout (basal) stage common to all groups, in which the volunteers will consume their usual diet with restriction in the consumption of fresh garlic and garlic products, the intervention will start, with the consumption of black garlic for 12 weeks. Volunteers will be provided with black garlic and they will ensure that no other type of garlic or culinary seasoning is used. Dietary and physical activity questionnaire according to the "Global Physical Activity Questionnarie (GPAQ)" will be compiled in order to collect information on habits and lifestyle, as well as to ensure the compliance of food restrictions. During the study, visits will be scheduled on the first day and last day of each stage. The subjects will come to the Unit on fasting conditions and will provide the first morning urine. Blood sample will be taken, plasma aliquoted and stored at -80°C until analysis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 62
Est. completion date November 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria: Healthy Group: - Total blood cholesterol levels of less than 200 mg/dL - LDL-cholesterol levels of less than 135 mg/dL - Not suffer from any other pathology. - No drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism, etc. Cardiovascular Risk Group: - Total cholesterol levels between 200-300 mg/dL - LDL-cholesterol levels between 135-175 mg/dL. - No acute or chronic pathology, except hypercholesterolemia - No drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism, etc.). Exclusion Criteria: - Failure to meet any of the inclusion criteria

Study Design


Intervention

Dietary Supplement:
black garlic
Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks

Locations

Country Name City State
Spain Universidad Católica de Murcia (UCAM) Murcia

Sponsors (2)

Lead Sponsor Collaborator
Maria Pilar Zafrilla Rentero Instituto de Investigación y formación agraria y pesquera (IFAPA)

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Impact on blood pressure Blood pressure (diastolic, systolic) changes observed from baseline at day 0 compared to 12 weeks.
Primary Impact on lipid profile Plasma levels of total cholesterol, HDL, LDL, VLDL (very low-density lipoprotein), triglycerides, apolipoproteins A1 and B. changes observed from baseline at day 0 compared to 12 weeks.
Secondary Impact on blood cells (Hematology) Blood counts changes observed from baseline at day 0 compared to 12 weeks.
Secondary evaluation of liver function to determine product safety Hepatic enzymes (GOT, GPT) changes observed from baseline at day 0 compared to 12 weeks.
Secondary Changes in cytokine levels Plasma levels of pro-inflammatory: IL-1ß, IL6 , TNF-a (tumor necrosis factor) and anti-inflammatory (IL-10, IL-17) cytokines. changes observed from baseline at day 0 compared to 12 weeks.
Secondary Changes in chemokine MCP-1 (monocyte chemotactic protein) Plasma levels of chemokine MCP-1 changes observed from baseline at day 0 compared to 12 weeks.
Secondary Changes in C reactive protein Plasma levels of C reactive protein changes observed from baseline at day 0 compared to 12 weeks.
Secondary Impact on endothelial function Plasma levels of nitric oxide, adhesion molecules VCAM-1 (vascular endothelial cell adhesion molecule), ICAM-1 (intercellular adhesion molecule), chemokines as markers of endothelium (E-selectin) and platelet (P-selectin) activation. changes observed from baseline at day 0 compared to 12 weeks.
Secondary Impact on glucose levels Plasma levels of glucose changes observed from baseline at day 0 compared to 12 weeks.
Secondary Impact on glycosylated hemoglobin (HbA1c) Plasma levels of glycosylated hemoglobin changes observed from baseline at day 0 compared to 12 weeks.
Secondary Impact in hormones related to metabolism Plasma levels of thyroid hormones (TSH, T3, T4). changes observed from baseline at day 0 compared to 12 weeks.
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A